Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.620
+0.030 (0.65%)
At close: Nov 21, 2025, 4:00 PM EST
4.440
-0.180 (-3.90%)
After-hours: Nov 21, 2025, 7:17 PM EST
Foghorn Therapeutics Revenue
Foghorn Therapeutics had revenue of $8.15M in the quarter ending September 30, 2025, with 4.42% growth. This brings the company's revenue in the last twelve months to $24.52M, down -3.91% year-over-year. In the year 2024, Foghorn Therapeutics had annual revenue of $22.60M, down -33.83%.
Revenue (ttm)
$24.52M
Revenue Growth
-3.91%
P/S Ratio
11.86
Revenue / Employee
$218,911
Employees
112
Market Cap
261.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.60M | -11.55M | -33.83% |
| Dec 31, 2023 | 34.16M | 14.93M | 77.63% |
| Dec 31, 2022 | 19.23M | 17.91M | 1,357.77% |
| Dec 31, 2021 | 1.32M | 889.00K | 206.74% |
| Dec 31, 2020 | 430.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FHTX News
- 17 days ago - Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update - GlobeNewsWire
- 19 days ago - Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript - Seeking Alpha
- 23 days ago - Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs - GlobeNewsWire
- 5 weeks ago - Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit - GlobeNewsWire
- 3 months ago - IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies - PRNewsWire
- 3 months ago - Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update - GlobeNewsWire
- 6 months ago - Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewsWire